Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 4547-4547 ◽  
Author(s):  
R. J. Motzer ◽  
T. de La Motte Rouge ◽  
A. L. Harzstark ◽  
M. D. Michaelson ◽  
G. Liu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

scholarly journals Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)

2016 ◽  
Vol 27 (3) ◽  
pp. 441-448 ◽  
Author(s):  
R.J. Motzer ◽  
A. Alyasova ◽  
D. Ye ◽  
A. Karpenko ◽  
H. Li ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Second Line

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy

2017 ◽  
Vol 15 (6) ◽  
pp. e1081-e1088 ◽  
Author(s):  
Annalisa Guida ◽  
Laurence Albiges ◽  
Lisa Derosa ◽  
Yohann Loriot ◽  
Christophe Massard ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study

2016 ◽  
Vol 14 (6) ◽  
pp. e595-e607 ◽  
Author(s):  
Stéphane Oudard ◽  
Florence Joly ◽  
Lionnel Geoffrois ◽  
Brigitte Laguerre ◽  
Nadine Houede ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Clinical Benefit ◽  
Renal Cell ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

scholarly journals A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma

BMJ Open ◽  
2019 ◽  
Vol 9 (12) ◽  
pp. e030522
Author(s):  
Yukari Bando ◽  
Nobuyuki Hinata ◽  
Takashi Omori ◽  
Masato Fujisawa
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Objective Response ◽  
Phase Iii ◽  
Power Calculation ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

IntroductionNivolumab has been proven to prolong overall survival as a second-line therapy for patients with advanced renal cell carcinoma (RCC) in a phase III clinical trial. However, versatile biomarkers have not been established to predict the efficacy of nivolumab against target disease.Methods and analysisAfter registration, screening test and serum-soluble programmed cell death 1-ligand 1 (sPD-L1) measurement will be performed by using the ELISA; patients will be grouped into high sPD-L1 or low sPD-L1 groups. Nivolumab (240 mg every 2 weeks by intravenous drip infusion) will be administered to each participant. For this prospective study, statistical power calculation indicated that 48 participants with metastatic or unresectable RCC are needed to assess the efficacy of this method. The participants must be at the age of at least 20 years at the time of informed consent and require second-line therapy after failure of first-line therapy or discontinuation due to adverse effects. All data will be collected in our institution. The primary endpoint is progression-free survival, and secondary endpoints are overall survival and objective response rate. In this protocol, we will examine sPD-L1 as a promising predictive marker.Ethics and disseminationThis protocol was approved by the Kobe University Clinical Research Ethical Committee (C180067). Findings of this study will be widely disseminated through conference presentations, reports, factsheets and academic publications; further generalisation will also be discussed.Trial registration numberUMIN000027873.

Everolimus as second-line therapy for metastatic renal cell carcinoma: a ‘real-life’ study

2015 ◽  
Vol 11 (2) ◽  
pp. 219-224 ◽  
Author(s):  
Mimma Rizzo ◽  
Gaetano Facchini ◽  
Clementina Savastano ◽  
Giuseppe Di Lorenzo ◽  
Luigi De Lucia ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Real Life ◽  
Second Line ◽  
Second Line Therapy ◽  
Life Study ◽  
Line Therapy ◽  
Real Life Study

Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma

Urology ◽  
2004 ◽  
Vol 63 (6) ◽  
pp. 1061-1065 ◽  
Author(s):  
Peter E. Clark ◽  
M.Craig Hall ◽  
Antonius Miller ◽  
Kevin P. Ridenhour ◽  
Diana Stindt ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Vinorelbine and interferon-α2c as second-line therapy in metastatic renal cell carcinoma

2000 ◽  
Vol 11 (3) ◽  
pp. 175-179 ◽  
Author(s):  
Manuela Schmidinger ◽  
Günther G Steger ◽  
Alexandra C Budinsky ◽  
Catharina Wenzel ◽  
Thomas Brodowicz ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document